MedTrace Logo

Phase I Study With AZD2171 in Patients With Advanced Solid Malignant Tumors and Liver Metastases

NCT00501605 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2011-01-21

No results posted yet for this study

Summary

Single centre recruiting approximately 80 patients who are given a rising single, followed by multiple, ascending oral dose of AZD2171, assessing the safety and tolerability of AZD2171 in patients with solid tumors and metastatic liver disease.

Conditions

  • Advanced Solid Tumor
  • Liver Metastases

Interventions

DRUG

AZD2171

Sponsors & Collaborators

Principal Investigators

  • Nick Botwood, BSc, MBBS, MRCP, MFPM · AstraZeneca

  • J. Drevs, PD · Klinik fur.Internistische Onkologie

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-02-28
Primary Completion
2005-04-30
Completion
2006-02-28

Countries

  • Germany

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00501605 on ClinicalTrials.gov